Search

Displaying results 2791 - 2800 of 8010 in total
  1. Drug

    Bacillus calmette-guerin substrain russian BCG-I live antigen

    go.drugbank.com/drugs/DB16648
    ApprovedInvestigational

    Bacillus Calmette-Guerin (BCG) substrain Russian BCG-I is a live BCG vaccine administered directly into the bladder for the adjuvant treatment of papillary urothelial cell carcinoma of the bladder. … Live BCG vaccines administered intravesically have been a gold standard therapy in the adjuvant treatment of non-muscle-invasive bladder cancers for decades,[A232264] used after tumor resection, and are

  2. Drug

    Abiraterone

    go.drugbank.com/drugs/DB05812
    ApprovedInvestigational

    [A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April,[A260880] July,[L47745] and September 2011,[A260880] respectively. … [L54773,L54768] As abiraterone has poor oral bioavailability and is susceptible to hydrolysis by esterases, abiraterone acetate was developed as an orally bioavailable prodrug with enhanced stability

  3. Drug

    Roxithromycin

    go.drugbank.com/drugs/DB00778
    ApprovedInvestigationalWithdrawn

    It is marketed in Australia as a treatment for respiratory tract, urinary and soft tissue infections. … Roxithromycin exerts its antibacterial action by binding to the bacterial ribosome and interfering with bacterial protein synthesis.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  4. Drug

    Caroxazone

    go.drugbank.com/drugs/DB09254
    ApprovedWithdrawn

    However, it presents a five-fold preference for the MAO-B subtype. … Caroxazone is an antidepressant that has been withdrawn from the market. It is a reversible monoamine oxidase inhibitor (MAOI) of both A and B monoamine oxidase subtypes.

  5. Drug

    Ponatinib

    go.drugbank.com/drugs/DB08901
    ApprovedInvestigational

    Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.

  6. Drug

    ATG-Fresenius S

    go.drugbank.com/drugs/DB05320
    Investigational

    ATG-Fresenius S is an immunosuppressive product for the prevention and treatment of acute rejection following organ transplantation. … ATG-Fresenius S is a concentrated anti-human T-lymphocyte immunoglobulin preparation derived from rabbits after immunization with a T-lympoblast cell line.

  7. Drug

    Tilmanocept

    go.drugbank.com/drugs/DB15373
    ApprovedInvestigationalWithdrawn

    Tilmanocept is under investigation in clinical trial NCT03241446 (Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed

  8. Drug

    Tromethamine

    go.drugbank.com/drugs/DB03754
    ApprovedInvestigational

    (From Merck, 11th ed; Martindale, The Extra Pharmacopoeia, 30th ed, p1424) … It is used in the synthesis of surface-active agents and pharmaceuticals; as an emulsifying agent for cosmetic creams and lotions, mineral oil and paraffin wax emulsions, as a biological buffer, and used

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    MBO7133

    go.drugbank.com/drugs/DB04999
    Experimental

    MB07133 is a HepDirect prodrug of an activated form of cytarabine (araC), an anti-cancer drug that is used to treat leukemia but is ineffective against primary liver cancer. … MB07133 uses our HepDirect technology to target a prodrug form of araCMP specifically to the liver.

  10. Drug

    Methylphenidate

    go.drugbank.com/drugs/DB00422
    ApprovedInvestigational

    for children, adolescents, and adults as recommended by CADDRA (Canadian ADHD Resource Alliance). … [L6037] CADDRA recommends the use of methylphenidate due to long term studies, of over twenty years in duration, which show methylphenidate is safe and effective.

    Categories: Psychostimulants, Agents Used for ADHD and Nootropics